Skip to Main Content

Intra-Cellular Therapies, maker of an approved treatment for schizophrenia and bipolar depression, announced positive results from a new clinical trial on Tuesday that could potentially expand use of its drug to other types of mood disorders.

Sales of the Intra-Cellular drug, called Caplyta, tripled last year to $249 million. The new study results, while not definitive, bolster confidence that the drug could also prove effective for people with major depressive disorder and so-called mixed features.


“We believe the long-term Caplyta opportunity could double to $2.5 billion-plus,” said RBC analyst Brian Abrahams, in a research note to clients on Tuesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.